Skip to the reading

[American Peptide Supply](/)

Four chapters on the supply picture

- [01 The change](/#the-change)

- [02 The history](/#the-history)

- [03 Who does what](/#who-does-what)

- [04 Keeping care](/#keeping-care)

A U.S. supply guide · Read on 27 October 2026

# Your care questions need a personal conversation

Care plans, shortage reports and safety concerns have different routes. Here’s where each conversation belongs.

## Some questions need a real conversation

We give no medical advice and sell nothing. There’s no patient inbox or contact form here, and no way to request a medicine or appointment. This is a reading guide.

A shortage explanation can help you put a question into words. It can’t assess symptoms, review a medical history or decide what treatment fits. Personal care questions need a professional who can do that work with you.

The National Library of Medicine also distinguishes [general information from personal medical advice](https://www.nlm.nih.gov/web_policies.html). That’s the line these pages follow: background for a conversation, rather than an answer about your own treatment.

![An open laptop and a headset beside a chair in a private alcove set aside for a video consultation.](/aps-calendar-3ef9e129bd73/talk-with-the-right-person.webp)

A private video consultation can be one route to a licensed prescriber. The personal assessment still matters, whichever route you use.

## For the plan that belongs to you

A licensed U.S. clinician who can prescribe is the route for questions about an interruption or a possible alternative. That may be an in-person visit or lawful telehealth. This guide can’t choose a medicine for you.

For a preparation already dispensed, the pharmacist can explain what it is and the instructions. A change to the treatment plan also needs the prescribing clinician. The shortage headline can give context, but it can’t take either person’s place.

You don’t need an account or personal health details to read these pages. The chapters and their sources are here to read without sending us anything.

## For information about a possible shortage

FDA’s [search and reporting page](https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages) explains how to check the database first. It gives separate routes for reporting a possible new shortage and sharing information about an existing one.

A shortage report gives FDA information about supply. It won’t arrange a prescription or settle your treatment plan. That part still belongs in the conversation with your care professionals.

### Public record, personal care

FDA handles national supply information. Your clinician addresses your treatment plan. Both questions can matter at the same time.

## For a medicine-related problem

FDA’s [semaglutide safety alert](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded) explains reporting medication errors and side effects through MedWatch, its safety-reporting program. A report alerts the agency to a problem; it doesn’t provide treatment or replace medical attention.

The references page lists the original documents behind our explanations. Each note says what a source helps you understand.

## Sources for this reading

- [NLM Web Policies — medical information](https://www.nlm.nih.gov/web_policies.html)

- [Drug Shortages — search and reporting routes](https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages)

- [FDA alert about dosing errors with compounded injectable semaglutide](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded)

Read on 27 October 2026. [All readings and their context](/references).

[Find the original reading behind a statement](/references)

We follow the supply calendar as a guide; we are neither a clinic nor a pharmacy, and we sell nothing.

[References](/references)

[About](/about)

[Contact](/contact)

© 2026 American Peptide Supply